The reduction of ormaplatin (tetraplatin), a prototype for Pt(IV) anticancer prodrugs, by glutathione (GSH) was kinetically characterized over a wide pH range at 25.0 °C and 1.0 M ionic strength. The reduction follows overall second-order kinetics, giving rise to the oxidized glutathione as the oxidation product, which was identified by high-resolution mass spectrometry. The reaction mechanism put forward involves parallel attacks by all the GSH species on the Pt(IV) prodrug as rate-determining steps. All rate constants for the rate-determining steps have been derived for the first time, enabling the construction of the reactivity of GSH species versus their pH distribution diagram. The diagram clearly displays that only one out of the five...
The binding of cisplatin to metallothionein (MT) was investigated at 37°C in 10 mM Tris-NO3 (pH -7.4...
For the synthesis and selection of active platinum-based anticancer drugs that perform better than c...
For the synthesis and selection of active platinum-based anticancer drugs that perform better than c...
Glutathione (GSH) reduction of the anticancer-active platinum(IV) compounds trans-[PtCl4(NH3)(thiazo...
The binding of platinum (Pt) drugs (oxaliplatin, carboplatin, and cisplatin) to glutathione (GSH, 6....
The development of Pt(IV) anticancer prodrugs to overcome the detrimental side effects of Pt(II)-bas...
The development of Pt(IV) anticancer prodrugs to overcome the detrimental side effects of Pt(II)-bas...
Reduction of the anticancer trans platinum(IV) prodrug JM335 by thiols in a moderately alkaline aque...
SynopsisVarious protolytic species of thiols RSH (thioglycolic acid, l-cysteine, dl-penicillamine, a...
In this thesis reductions of model and anticancer active Pt(IV) complexes with thiols and ascorbic a...
The reactions of cisplatin [cis-diamminedichloroplatinum(II), CDDP] with glutathione (GSH) and drug ...
The study of Pt(IV) antitumor prodrugs able to circumvent some drawbacks of the conventional Pt(II) ...
The study of Pt(IV) antitumor prodrugs able to circumvent some drawbacks of the conventional Pt(II) ...
The study of Pt(IV) antitumor prodrugs able to circumvent some drawbacks of the conventional Pt(II) ...
Reduction of trans-[Pt(CN)4 X2]2- (X = Cl or Br) as model compounds for antitumour-active platinum(I...
The binding of cisplatin to metallothionein (MT) was investigated at 37°C in 10 mM Tris-NO3 (pH -7.4...
For the synthesis and selection of active platinum-based anticancer drugs that perform better than c...
For the synthesis and selection of active platinum-based anticancer drugs that perform better than c...
Glutathione (GSH) reduction of the anticancer-active platinum(IV) compounds trans-[PtCl4(NH3)(thiazo...
The binding of platinum (Pt) drugs (oxaliplatin, carboplatin, and cisplatin) to glutathione (GSH, 6....
The development of Pt(IV) anticancer prodrugs to overcome the detrimental side effects of Pt(II)-bas...
The development of Pt(IV) anticancer prodrugs to overcome the detrimental side effects of Pt(II)-bas...
Reduction of the anticancer trans platinum(IV) prodrug JM335 by thiols in a moderately alkaline aque...
SynopsisVarious protolytic species of thiols RSH (thioglycolic acid, l-cysteine, dl-penicillamine, a...
In this thesis reductions of model and anticancer active Pt(IV) complexes with thiols and ascorbic a...
The reactions of cisplatin [cis-diamminedichloroplatinum(II), CDDP] with glutathione (GSH) and drug ...
The study of Pt(IV) antitumor prodrugs able to circumvent some drawbacks of the conventional Pt(II) ...
The study of Pt(IV) antitumor prodrugs able to circumvent some drawbacks of the conventional Pt(II) ...
The study of Pt(IV) antitumor prodrugs able to circumvent some drawbacks of the conventional Pt(II) ...
Reduction of trans-[Pt(CN)4 X2]2- (X = Cl or Br) as model compounds for antitumour-active platinum(I...
The binding of cisplatin to metallothionein (MT) was investigated at 37°C in 10 mM Tris-NO3 (pH -7.4...
For the synthesis and selection of active platinum-based anticancer drugs that perform better than c...
For the synthesis and selection of active platinum-based anticancer drugs that perform better than c...